MedWatch: an important instrument for postlicensing surveillance

被引:2
作者
Aledort, L. M. [1 ]
机构
[1] CUNY Mt Sinai Sch Med, New York, NY 10029 USA
关键词
D O I
10.1111/j.1538-7836.2006.02023.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1637 / 1637
页数:1
相关论文
共 4 条
[1]   Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity - reply to a rebuttal [J].
Aledort, LM .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (04) :822-822
[2]   Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VII inhibitor bypass activity [J].
Aledort, LM .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (10) :1700-1708
[3]   Thromboembolic adverse events after use of recombinant human coagulation factor VIIa [J].
O'Connell, KA ;
Wood, JJ ;
Wise, RP ;
Lozier, JN ;
Braun, MM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (03) :293-298
[4]   Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity - a rebuttal [J].
Sallah, S ;
Isaksen, M ;
Seremetis, S ;
Rojkjaer, LP .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (04) :820-822